GEO-Pharm SRL

GEO-Pharm reported total assets of 499,024 € at the end of the 2025 financial year (annual accounts filed with the NBB on 31 Aug 2026).

Company number (CBE) 0667.520.049 · VAT BE0667520049
1180 Uccle
active in Other liberal professions and professional, scientific and technical activities n.e.c. (NACE 74999)
operating since 07 Dec 2016 (≈ 10 yrs)
Public Public page: latest year only. The score, history and details open with a free account. Create a free account
Idonis solidity score
EDCBA

The score of GEO-Pharm shows with a free account.

See the score
Profile
SRL since 2016
Components
  • Summary? / 5
    • Balance sheet strength
    • Liquidity
    • Repayment capacity
    • Profitability
    • Trajectory
    • Compliance and register
  • Position in its sectorvs peers
  • Supplier creditat 30 d
  • Borrowing capacityborrowable
  • Valuationcentral

Visible once signed in: create your account, the 14-day Pro trial is free.

Detail

Key figures 2025

Net result59,343 €
Equity477,760 €
Cash79,471 €
EBITDA116,342 €
Total assets499,024 €
The line marks its sector median: 53.5% (188 companies).

Change 2022 → 2025: Equity +103 % Total assets +94 %

Accounts of the company itself (not consolidated).

The full file covers 8 financial years; a free account shows 2. →

Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error

GEO-Pharm's annual accounts

20252024202320222021
Net result59,343 €
Equity477,760 €
Cash79,471 €
EBITDA116,342 €
Total assets499,024 €

Filed annual accounts

  • Year ended 31 Dec 2025filed on 31 Aug 2026
  • Year ended 31 Dec 2024filed on 27 Aug 2025
  • Year ended 31 Dec 2023filed on 29 Nov 2024
  • Year ended 31 Dec 2022filed on 31 Oct 2023
  • Year ended 31 Dec 2021filed on 15 Nov 2022

GEO-Pharm's financial analysis

Management and control of GEO-Pharm

2 active director(s) in the register.

GEO-Pharm's shareholders and holdings →

GEO-Pharm's publications in the Belgian Gazette

Company number, VAT number and registered office

Company number (CBE)
0667.520.049
VAT number
BE0667520049
Peppol
Registered · 0208:0667520049 · as of 10 Nov 2026
Legal form
SRL
Incorporated
07 Dec 2016
Registered office
1180 Uccle
Latest accounts
2025 · filed on 31 Aug 2026
Activity
Other liberal professions and professional, scientific and technical activities n.e.c. (NACE 74999)

GEO-Pharm (SRL) has been based in Uccle since 2016, active in: other liberal professions and professional, scientific and technical activities n.e.c.. For 2025, it reports a net profit of 59,343 € and equity of 477,760 €; its revenue is not published. Its solvency stands at 95.7%, above the median of its sector (53.5%).

Guide: Reading Belgian SME accounts: the five figures that count →

Companies similar to GEO-Pharm

Companies in the same business, of comparable size and area, outside its group.

Frequently asked questions about GEO-Pharm

What is the revenue of GEO-Pharm?

GEO-Pharm files its accounts in a format where revenue is optional: it is not published for 2025.

What is the VAT number of GEO-Pharm?

In Belgium, the VAT number is the company number prefixed with BE: BE0667520049 for GEO-Pharm, if the company is VAT-registered. Its company number (CBE) is 0667.520.049.

Where is the registered office of GEO-Pharm?

According to the CBE register, the registered office of GEO-Pharm is in 1180 Uccle.

What is the equity of GEO-Pharm?

At the close of the 2025 financial year, the equity of GEO-Pharm amounts to 477,760 €, a solvency of 95.7% of total assets.

Who manages GEO-Pharm?

The register lists 2 active mandates at GEO-Pharm. Names and roles are in the full file, with the deeds published in the Belgian Gazette.

Idonis

The full file of GEO-Pharm

Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.

Open the full file →
Free account in 30 seconds, by email. No bank card.
Sources : Annual accounts — NBB ↗ Register — CBE ↗ Deeds — Belgian Gazette ↗ · Updated on 04 Sep 2026

No credit card, no commitment.

What each plan unlocks →